Skip to main content



Save the Date for 

Clinical Epigenetics International Conference - CLEPIC 2024

Warsaw Poland, June 05 – 07, 2024

More information coming soon at

Early bird registration extended by 12-05-2024

Welcoming words from Lucia Altucci and Marianne Rots, Editors in Chief of Clinical Epigenetics:

The need to meet and greet

Scientists need to meet to stay up-to-date within and beyond one’s own research field, to exchange and fuel new ideas, to keep inspired and to inspire others. Corona-volente, we aim to offer you such platform by bringing together the editors, authors and readers of Clinical Epigenetics as well as the newly launched Epigenetics Communications. Moreover, we will invite industrial partners and public bodies, with a focus on training the next generation of multidisciplinary multi-epiomics scientists. This conference starts a series of annual conferences devoted to fully exploiting the many applications of epigenetics in health and disease as well as in all kingdoms of life (biotech, crop breeding, etc.).

Looking forward to meeting and greeting many of you in a relaxed atmosphere full of state-of-the-art epigenetics!

EpiBio Conference

New Content Item

Click here for more information.

Call for Papers: Epigenetic Mechanisms in Developmental Origin of Health and Disease

This Collection focuses on the most recent advances in epigenetic research pertaining to Developmental Origins of Health and Disease (DOHaD), including mechanistic, targeted, and genome-wide epigenetic analyses. We encourage submissions encompassing studies focused on epigenetics in DOHaD to increase our understanding of developmental epigenetic plasticity, how it conditions health postnatally, and the possible translation of this knowledge into clinical practice.

New thematic series: Multiscale chromatin dynamics

New Content ItemWe are proud to announce a new cross-journal thematic series between Epigenetics Communications and Clinical Epigenetics, guest edited by Pernette Verschure and Wim Vanden Berghe. The last few years have seen a wealth of knowledge on the role of epigenetic gene regulation in (patho-)physiological processes. New insights relate to the highly dynamic nature of epigenetic systems. Epigenetic regulatory proteins are in constant motion in the nucleus, exchanging between chromatin-bound and unbound states. In addition,  various layers of chromatin folding show defined dynamics. The causal relationship between these dynamics of chromatin and nuclear organization with gene activity and silencing is still an open question of great importance. Find out more about the scope here.

Find Best-Fit Journal for your article!

Choosing the right journal is essential for every author, and we are fully committed to collaborating across our prestigious epigenetics journals to assist you in this process. To facilitate an informed decision, we offer a concise overview of our three journals. For more detailed information on each one, simply click on the journal title below: 

New Content ItemClinical Epigenetics

Epigenetics & Chromatin 

Epigenetics Communications

Our dedicated Editors, with their extensive expertise in the field, will carefully evaluate your submission. If they believe that another journal within our network may better align with your research, they will propose a transfer during the peer-review process. This transfer will significantly expedite the handling of your submission, eliminating the need for additional peer-review rounds. We value your research and are here to support you every step of the way. Explore our options and make the most of our collaborative efforts to ensure your work reaches its full potential. 

Editorial Policy Regarding Submissions describing “Negative Outcome Studies”

Provided that the methodology is consistent and sound, and the research question brings added value to the field, we warmly welcome ‘negative results’ studies. Manuscripts to be considered include, but are not limited to, descriptions of:

  • (failed) attempts to reproduce previously published data
  • irreproducible data between two (collaborating) laboratories
  • failed, but technically solid, attempts to prove a scientific hypothesis

Manuscripts which will not be considered include:

  • bioinformatic analyses without a solid statistical approach
  • "stand alone" bioinformatic analyses without experimental proof

Editorial Policy Regarding Submissions Focusing on Non-coding RNAs or RNA Modifications

Since epigenetic regulation and associated aspects of transcription regulation are wide-spread and complex, Epigenetics Communications aims to focus on those aspects of ncRNA-induced epigenetic regulation that concern changes in chromatin organization. As such manuscripts on non-coding RNAs or RNA modifications are only acceptable for the journal when including: 

  • data on the molecular epigenetic regulation of the expression of non-coding RNA (or its modifying enzymes) or
  • insights on the mechanism of action of the non-coding RNA on the chromatin and/or functioning of the DNA or
  • insights in mitotic stability of the RNA-induced effect

Editorial Policy Regarding Submissions Focusing on In silico research

Manuscripts reporting on straightforward bioinformatic analyses of publicly accessible databases only, cannot be considered for publication in Epigenetics Communications, unless the manuscript presents:

  • new, convincingly-described, scientific insights which will impact the field and/or
  • additional insights into underlying biological mechanisms (“wet-lab” validations) and/or
  • validations of findings in a replication cohort


Lucia Altucci, Università degli Studi della Campania, Italy
Marianne Rots, University Medical Center Groningen, Netherlands  

Aims and scope

Epigenetics Communications covers the broad spectrum of epigenetic science from basic research to technological and therapeutic innovations, as well as their theoretical, ethical and societal dimensions. Epigenetics Communications is an innovative new, open-access journal devoted to the study and problematization of epigenetic principles and mechanisms in basic and translational research settings. It is also a forum for interdisciplinary debates around epigenetics, as well as for the investigation of its societal dimensions. In support of open science initiatives, the journal will have a level 4 data policy requiring data be made publicly available. The journal is divided into the following sections:

  • Molecular Epigenetics (Histone Modifications; DNA Methylation; DNA Demethylation)
  • Nuclear Organization
  • Mitotic & Meiotic Heritability
  • Epigenetic Drugs
  • Epigenetic Technologies
  • Epigenetic Bioengineering
  • Network Epigenetics
  • Computational Epigenomics
  • Single Cell Epigenetics
  • Epigenetic Toxicology
  • Model Organisms (Vertebrates; Invertebrates; Plants; Unicellular systems)
  • Epigenetics and Society

Epigenetics Communications will support the publication of manuscripts that contribute to a further understanding of epigenetic mechanisms that impact functioning of systems and organisms. Submissions describing clinical applications are referred to the sister journal, Clinical Epigenetics.

This new and innovative journal will also act as a forum to showcase and discuss alternative conclusions/interpretations of well-established epigenetic phenomena. These can be based either on the (re-)analyses of published and/or new data, or on the findings and results of epigenetic research in interaction with other disciplines. As such, we welcome 'systematic’ and ‘critical’ studies, be them positive (expected) or negative (non-expected) with respect to their outcomes.

Affiliated with

  • Epigenetics Communications is affiliated with the International Society for Molecular and Clinical Epigenetics (isMOCLEP). isMOCLEP is open to all those interested in the wide spectrum of epigenetic research, from molecular to clinical aspects. isMOCLEP community welcomes academic researchers, early career scientists, companies, policy makers, and beyond.

Annual Journal Metrics

2023 Speed
6 days submission to first editorial decision for all manuscripts (Median)
10 days submission to accept (Median)

2023 Usage 
25 Altmetric mentions